We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 538

News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry and staff titled "Molecular Diagnostic Instruments with Combined


RAND Corp. predicts $44.2 billion in savings with biosimilars
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The Rand Corp. has issued a perspective titled "The Cost Savings Potential of Biosimilar Drugs in the United States." It predicts that "biosimilars


Ranbaxy loses FDA approval for two generics
  • Shook Hardy & Bacon LLP
  • India, USA
  • November 13 2014

According to a statement that Ranbaxy Laboratories Ltd. provided to the Bombay Stock Exchange Website, the U.S. Food and Drug Administration (FDA


FTC settles deceptive sales-tactics claims against MPHJ Technology
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The U.S. Federal Trade Commission (FTC) has agreed to settle claims that MPHJ Technology Investments, LLCa patent-assertion entity (PAE)and company


Dissatisfied patent reexamination plaintiff contends standing conferred by statute
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

A consumer-interest organization that was dissatisfied by a Board of Patent Appeals and Interferences (BPAI) ruling in the appeal of a patent


CNS drug approvals take longer, are rejected more often
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

A new Tufts Center for the Study of Drug Development report reveals that drugs to treat central nervous system (CNS) disorders take longer to develop


Bio-Rad agrees to pay $55 million to resolve SEC bribery charges
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

A California-based clinical diagnostic and life science research company has reportedly agreed to pay $55 million to resolve U.S. Securities and


Ninth Circuit rules out state’s claims in class settlement with fetal-gender testing co
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The Ninth Circuit Court of Appeals has enjoined California's effort to obtain restitution on behalf of individual citizens bound by the bargainedfor


College research program partners with diagnostics firm
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The Baylor College of Medicine and diagnostics company Miraca Holdings have reportedly formed a joint ventureBaylor Miraca Genetics


Tech interests praise USPTO director nomination
  • Shook Hardy & Bacon LLP
  • USA
  • October 30 2014

According to a news source, technology industry interests have lauded President Barack Obama's (D) choice for U.S. Patent and Trademark Office